Ethylenediamine Derivatives for Selective Bradykinin Receptor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhibitors targeting bradykinin receptors for anti-tumor effects, such as PL-AC-15 and PL-AC-202, have limitations in efficacy and specificity, necessitating the development of more potent and selective compounds to inhibit cancer cell proliferation, migration, and invasion.
Innovation Solution
Development of ethylenediamine derivatives with specific structural modifications, including various substituents and ring formations, to target bradykinin receptors (B1R and B2R) and inhibit the MAPK pathway, thereby reducing cancer cell proliferation and invasion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing inhibitors such as PL-AC-15 and PL-AC-202 are used to target bradykinin receptors, then anti-tumor effects are achieved, but efficacy and specificity are limited
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10) at different positions of the ethylenediamine core structure. Each substituent can be independently selected from specific chemical groups to optimize binding affinity for B1R and B2R receptors, thereby improving both efficacy and specificity simultaneously
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure parameters of the ethylenediamine derivatives, including different substituent types, ring structures, and molecular weights. This allows optimization of the compound's interaction with bradykinin receptors to achieve enhanced anti-tumor efficacy and improved receptor specificity
2Reliability
If ethylenediamine derivatives with complex structural modifications are developed to improve efficacy, then anti-tumor effect is enhanced, but structural complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the ethylenediamine derivative into distinct functional modules: the core ethylenediamine structure, various substituent groups (R1-R10), and optional ring structures. This modular approach allows systematic optimization of each segment to enhance efficacy while maintaining manageable structural complexity through organized design
Solution Approach 2:
The patent employs universality by designing the ethylenediamine core structure to serve multiple functions: it provides the foundational scaffold for receptor binding, allows for diverse substituent attachment to target different receptor subtypes (B1R and B2R), and enables optimization of pharmacokinetic properties, thereby achieving enhanced efficacy without proportionally increasing complexity
Data Source
AI summary
Disclosed in the present application are an ethylenediamine derivative, and a preparation method therefor and a use thereof. The structural formula of the ethylenediamine derivative is represented by Formula I. The compound can be prepared by an artificial synthesis method, has a broad-spectrum anti-tumor effect, can prolong the survival period of a tumor patient, and improves the quality of life of the tumor patient. The compound has a stable drug effect and low toxicity, is easily accepted by a human body, can be applied to the treatment of most cancers, and has certain advantages compared with currently listed anti-tumor drugs.